Loading stock data…
Vericel Corporation (VCEL)
$39.08-1.11 (-2.76%)
Market ClosedLast close Sep 8
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vericel Corporation in the Healthcare sector is trading at $39.08 with a market capitalization of $2.3B. Wall Street consensus targets $60.57 (7 analysts), implying a +55.0% move over the next 12 months. The stock is currently 21% below its 52-week high of $49.32, remaining 2.4% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +55.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 24) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $77.46M↑ | $68.42M↓ | $92.92M↑ | $67.50M↑ | $63.24M |
| Gross Profit | $56.40M↑ | $49.27M↓ | $73.13M↑ | $49.59M↑ | $46.61M |
| Operating Income | $434,000↑ | -$8.06M↓ | $22.41M↑ | $3.45M↑ | -$2.03M |
| Net Income | $2.21M↑ | -$6.30M↓ | $23.24M↑ | $5.07M↑ | -$553,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North Ame...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.26B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
92.08
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.07
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.55%
Volume
Today's trading volume
409,852
Recent News
MediWound Q2 Earnings Call Highlights
MediWound (NASDAQ:MDWD) reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, as the company continued investing in its Phase III EscharEx chronic-wound program and expanded development work around its NexoBrid burn treatment. Chief Executive Officer Ofer Gone
Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison
IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a […]
Vericel Q2 Earnings Call Highlights
Vericel (NASDAQ:VCEL) reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and cash generation. Total revenue rose 22% from a year earlier to $77.5 million, e
Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates
Vericel (VCEL) delivered earnings and revenue surprises of +200.00% and +7.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests
Focused on regenerative therapies for sports medicine and burn care, this biopharma firm reported a notable insider sale in June.